David O. Antonuccio received his B.A. (1975) in psychology (honors) and economics from Stanford University. He received his M.A. (1979) and Ph.D. (1980) in Clinical Psychology from the University of Oregon. He is a Professor Emeritus in the Dept. of Psychiatry and Behavioral Sciences at the University of Nevada School of Medicine and a former faculty member at the Fielding Graduate University. He lives in Reno and served on the Nevada State Board of Psychological Examiners from 1990 to 1998. His clinical and research interests include the behavioral treatment of depression, anxiety, and smoking. He holds a diplomate in Clinical Psychology from the American Board of Professional Psychology and is a Fellow of both the American Psychological Association and the American Psychological Society. He was named Outstanding Psychologist in 1993 by the Nevada State Psychological Association (NSPA), received an Award of Achievement from NSPA in 1999 for his work on depression, was named the 2000 recipient of the McReynolds Foundation Psychological Services Award for "outstanding contributions to clinical science", and received the APAHC (Association for Psychologists in Academic Health Settings) Bud Ogel Award for Distinguished Achievement in Research in 2006. He was named the 2011 recipient of the Ira Pauly Award for outstanding residency teaching in psychiatry at the University of Nevada School of Medicine. His articles on the comparative effects of psychotherapy and pharmacotherapy have received extensive coverage by the national media and are models of careful scholarship. He is author or coauthor of Psychotherapy vs. medication for depression: Challenging the conventional wisdom with data (1995), Psychotherapy for depression: No stronger medicine (1995), Separating good marketing from good science (1996), No need to panic (1997), Depression: Psychotherapy is the best medicine (1997), A cost-effectiveness analysis of cognitive behavior therapy and fluoxetine (Prozac) in the treatment of depression (1997), Raising questions about antidepressants (1999), Antidepressants vs. placebos: Meaningful advantages are lacking (2002), Antidepressants: A triumph of marketing over science? (2002), Psychology in the prescription era: Building a Firewall between Marketing and Science (2003), a Patient Bill of Rights for Psychotropic Medications (2011), and Relabeling the Medication We Call Antidepressants (2012).